What Happened?
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 1.5% in the afternoon session after RBC Capital Markets raised its price target on the company. The investment bank increased its forecast for the stock's price to $50 from a previous target of $46. This move suggests that the analyst sees a higher potential value for the company's shares. However, it is important for investors to note that RBC maintained its "Sector Perform" rating on Exact Sciences. This type of rating indicates that the firm expects the stock to perform in line with the broader healthcare diagnostics sector, rather than significantly outperforming it. The price target adjustment without a formal rating change often reflects updated financial modeling or a revised view on market conditions.
After the initial pop the shares cooled down to $48.76, up 1.5% from previous close.
Is now the time to buy Exact Sciences? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Exact Sciences’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 21 days ago when the stock gained 7.9% on the news that markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Exact Sciences is down 14.3% since the beginning of the year, and at $48.76 per share, it is trading 32.2% below its 52-week high of $71.93 from October 2024. Investors who bought $1,000 worth of Exact Sciences’s shares 5 years ago would now be looking at an investment worth $638.22.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.